Italia markets closed

Sana Biotechnology, Inc. (SANA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
24,98-0,73 (-2,84%)
Alla chiusura: 4:00PM EDT

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98020
United States
206 701 7914

Impiegati a tempo pieno321

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Steven D. HarrPres, CEO & Director829,25kN/D1970
Dr. Richard C. MulliganExec. Vice Chairman & Head of SanaX954,45kN/D1955
Mr. Christian Hordo M.B.A.Sr. VP & Chief Bus. Officer485,03kN/D1983
Mr. Nathan Hardy M.B.A.Sr. VP & CFON/DN/D1976
Ms. Shanna Clouse PeekSr. VP & Head of Corp. OperationsN/DN/DN/D
Brittany MccleeryAccounting Mang.N/DN/DN/D
Dr. Edward Rebar Ph.D.Sr. VP & CTON/DN/D1968
Mr. James J. MacDonald J.D.Exec. VP, Gen. Counsel & Sec.N/DN/D1975
Ms. Robin AndrulevichExec. VP & Chief People OfficerN/DN/D1966
Dr. Sunil AgarwalExec. VP, Head of Devel. & Chief Medical OfficerN/DN/D1970
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Sana Biotechnology, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.